Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non–small cell lung cancer (NSCLC).
Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non—small cell lung cancer (NSCLC).
After findings from the PACIFIC trial were presented at the 2017 ESMO Congress many practices, such as Levine Cancer Institute, added durvalumab (Imfinzi) as a consolidation treatment after concurrent chemoradiation. Durvalumab, a PD-L1 inhibitor, improved median progression-free survival by 11.2 months compared with placebo (16.8 vs 5.6 months; HR, 0.52; 95% CI, 0.42-0.65; P <.0001).
In February 2018, the FDA granted approval of durvalumab for the treatment of patients with locally advanced, unresectable stage III NSCLC who have not progressed following chemoradiotherapy. Durvalumab has become the new benchmark for stage III NSCLC, says Kim.